From Algorithm to Aisle: What Naritas CEO Nora Keldy Teaches Us About Building AI-Native Life Sciences Companies

In 2014, Nora Keldy sat down with a matrix. She was a mathematician and computer scientist who had spent years in drug discovery, and she had just moved into nutrition. What she found there looked less like an industry and more like a graveyard of century-old ingredients, reformulated and repackaged, but never fundamentally rethought. Consumers were changing. The ingredients were not.

So Nora built Naritas — a Dublin-based biotech that uses AI to discover peptide-based ingredients from natural sources and move them through clinical validation, regulatory approval, manufacturing scale-up, and into products sold on six continents. Today the company counts U2's Bono and The Edge among its investors, and its ingredients are inside food, beverage, and supplement products across every major global market.

The latest episode of Qualio's From Lab to Launch podcast covers Nora's journey in full. Three themes from that conversation apply directly to how life sciences companies think about AI, quality, and the infrastructure required to scale.

1. AI only works if you feed it — and feeding it is the hard part

Naritas built what Nora calls the Magnifier Discovery Platform: an AI system that evaluates peptide candidates not just for efficacy, but for oral bioavailability, heat stability, allergenicity, formulation stability, and cost of production. The platform does not advance a molecule into biological testing until it clears all those dimensions simultaneously.

This is a fundamentally different architecture from the traditional ingredient discovery model, where molecules were tested one-by-one in labs, mostly at random, at enormous cost and over decades.

But the architectural advantage only holds as long as the data keeps flowing. Nora made that point directly: during COVID, when everything was being cut, she faced pressure from shareholders to stop investing in the AI platform itself and redirect all resources to commercializing existing ingredients. She refused.

"AI, you constantly need to feed it for it to become better and better. And the feeding in our space is expensive. It's not like it's feeding off literature. You have to actually create the data yourself — biological data."

She cut headcount, closed projects, and deferred spend elsewhere. But she protected the AI investment. Looking back, she calls it one of the clearest decisions she made.

The lesson for life sciences leaders: an AI system that stops receiving validated, structured data degrades. The competitive advantage is not in deploying AI once. It is in building the operational infrastructure that keeps high-quality data flowing into it continuously.

2. Quality is not a gate at the end of innovation — it is a constraint baked into the discovery model

Naritas works with some of the largest consumer goods and ingredient companies in the world: BASF, Nestlé, Mars, Givaudan. Those companies do not enter co-development agreements unless a supplier's quality and safety standards are demonstrably at their level.

Nora was unambiguous about this in the conversation:

"You can find a molecule that does something incredible from a health perspective. But if that molecule is not producible, if it's not stable in formulation, if the quality isn't there — that would kill the project, no matter how great your molecule is."

This is a framing that many early-stage life sciences companies get wrong. Quality is treated as something to build once the science is validated. At Naritas, it is part of the validation. The AI platform screens for manufacturability and regulatory friendliness before a single wet lab experiment is run. The team that handles supply, manufacturing, and quality control was built in parallel with the science team, not after it.

The implication is direct: companies that delay building quality infrastructure until they have something to protect almost always discover the cost of that delay at the worst possible moment — during a clinical hold, a partnership diligence process, or an audit. The companies that build continuous compliance infrastructure early treat quality as a growth lever, not an overhead.

That is exactly the argument behind why compliance architecture determines clinical outcomes — and why teams that build it late find themselves doing heroics before IND rather than running confidently toward it.

3. Scaling is not a headcount problem — it is an architecture problem

When Naritas entered its commercial phase, the question was not how many people to hire. It was how to scale ingredients across markets, distribution channels, and product categories without the organization breaking down under the complexity.

Nora's answer was architecture: the right investor partners in the proof-of-concept phase, the right enterprise co-development partners in the validation phase, and the right distribution and brand partners in the commercial phase. Different stages required different partnerships. But across all of them, the underlying quality and regulatory infrastructure had to hold.

This maps directly onto what Qualio's team has been documenting across hundreds of growth-stage life sciences companies. The distinction between episodic readiness and continuous readiness is not a compliance philosophy question — it is a scaling question. Companies that rebuild their quality system from scratch before each audit do not scale. Companies that run compliance continuously do not have that problem.

Nora's experience reinforces a point that is easy to miss when you are raising your Series A and trying to survive COVID: the ceiling on your commercial velocity is often not your science, your funding, or your sales motion. It is whether your quality system was built for clinical demands or for the earlier phase you needed to survive.

The category Naritas created — and what it demands of operations

When Nora started Naritas in 2014, she noted that most people heard "AI" and thought it stood for artificial insemination. Peptides were largely unknown outside pharma. She was not entering a category. She was creating one.

April Dunford's positioning framework makes a useful distinction here: the category you choose to operate in sets the buyer's evaluation criteria, the competitive set, and the questions your evidence has to answer. Naritas chose a category that did not exist and built proof points — three double-blind, placebo-controlled clinical trials for PeptiStrong alone — before the market understood what it was buying.

That is a high-risk, high-return bet. And it requires that every other part of the operation be extremely reliable. When the science is novel and the category is undefined, investors, partners, and regulators scrutinize everything else harder. Regulatory affairs, quality documentation, clinical data integrity — these are not support functions in a company making a category-creation bet. They are the credibility infrastructure that makes the bet legible to the outside world.

What Nora would tell early-stage founders

When Meg asked for parting advice, Nora's answer was immediate: adaptability.

"Adaptation is the largest and biggest skill set anyone can have for success, especially as an entrepreneur."

She had pivoted focus during COVID, built a direct-to-consumer brand purely to generate investor proof points when the clinical CRO shut down, cut projects that were not going to generate return, and held the line on the one investment — the AI platform — that most others would have cut first.

That kind of adaptability is not possible without operational clarity. You cannot adapt fast if you do not know where you stand. You cannot redirect resources if you cannot see which compliance gaps will surface in the next 90 days. The companies that adapted well through COVID — and through every disruption before and after — were the ones that had built quality systems that gave them genuine visibility, not just the appearance of compliance.

Listen to the full episode

Nora covers the Naritas origin story, the decision to bet on peptides before the market understood them, what it was like to meet Bono and The Edge, the co-development partnerships with BASF and Givaudan, and what she sees coming in the peptide and AI-driven ingredient space over the next three years.

Listen to the From Lab to Launch episode with Nora Keldy here.

Qualio helps life sciences companies build compliance infrastructure that scales with their ambition. If you are a growth-stage biotech building your quality system, see how Qualio works.